As the market for cell and gene therapies continues to expand, manufacturers and hospitals need help navigating the supply chain, from R&D to point-of-care.
Below are the three most significant issues we’ve identified when facilitating the relationship between the cell and gene therapy manufacturer and the hospital’s point-of-care.
Cell and gene therapy developers struggle with the ability to rapidly commercialize their new therapies to health care providers.
Hospitals need a partner to provide consistent access to innovative CGT therapies for patients throughout their entire network of hospitals and clinics.
Hospitals and CGT manufacturers lack consistent point-of-care assistance matched with the logistics of storing and distributing CGT products.
Cell and Gene Therapy Partnership
Using our extensive hospital partnerships, both domestic and global, matched with our 7 owned and operated cell collection centers, we can serve as both the CGT manufacturer's commercial distributor and the hospital's CGT supplier and point-of-care provider of CGT therapy.